Treatment with 0.1 and 1 μM CsA (doses corresponding to in vivo blood concentrations) leads to downregulation of gm-csf mRNA level in GL261 glioma cells (Fig. 4E). This evidence concerns the gene PPP1R3A and central nervous system cancer.